Last updated on October 28, 2025
No. Selling CBD food products in Germany without novel-food authorisation is prohibited under EU Regulation (EU) 2015/2283. All ingestible CBD items, including oils, snacks, and supplements, are classified as “novel foods” and require safety approval before entering the market.
The Temptation Behind the Trend
Imagine strolling through a trendy Berlin café and spotting CBD-infused brownies promising calm and wellness. Tempting? Absolutely. Legal? Not unless you’ve cleared one of the toughest regulatory hurdles in Europe. Germany, despite its progressive cannabis reforms, enforces strict compliance when it comes to CBD in food—and the reason lies in European law.
CBD has become a global wellness phenomenon, marketed as a natural solution for stress, sleep, and even pain relief. From sparkling drinks to protein bars, the possibilities seem endless. But in Germany, the glossy packaging hides a complex legal reality: CBD in food is not just another ingredient—it’s a regulated substance under the EU’s novel-food framework.
The Legal Framework
Under Regulation (EU) 2015/2283, any food not widely consumed in the EU before May 15, 1997, is considered a “novel food.” Cannabidiol falls squarely into this category. Before CBD can appear in your granola or gummy bear, producers must submit a detailed application to the European Commission, backed by safety studies reviewed by the European Food Safety Authority (EFSA). Only after authorisation can the product legally enter the market.
Germany’s Federal Office of Consumer Protection and Food Safety (BVL) confirms this position: CBD-containing foods are not marketable without authorisation. The Federal Ministry of Food and Agriculture (BMEL) echoes the same, stating that novel foods require prior approval to ensure consumer safety. As of today, no CBD food product has received EU authorisation, making any sale without it unlawful.
Why So Strict?
The caution stems from unanswered questions about CBD’s long-term effects. EFSA paused its risk assessment in 2022, citing gaps in data on liver toxicity and drug interactions. Until these concerns are addressed, regulators prefer to err on the side of safety. For businesses, this means compliance isn’t optional—it’s mandatory.
CBD interacts with the human endocannabinoid system, which influences mood, appetite, and sleep. While research suggests potential benefits, the lack of comprehensive toxicological data raises red flags for regulators. Questions remain about cumulative exposure, effects on vulnerable populations, and interactions with medications. This scientific uncertainty drives the EU’s conservative stance.
Market Reality
Despite the rules, CBD edibles still appear in online shops and wellness stores, often marketed as “food supplements.” But enforcement is tightening. German authorities have seized products and issued fines, signaling that the grey market era is ending. For entrepreneurs, the message is clear: invest in authorisation or risk penalties and product bans.
Retailers often try to bypass restrictions by labeling CBD products as “aromatherapy” or “not for consumption,” hoping consumers will ignore the disclaimer. However, such tactics do not shield businesses from liability. Courts in Germany have repeatedly upheld bans on CBD foods, reinforcing that compliance is non-negotiable.
Cultural and Economic Context
CBD’s popularity in Germany mirrors a global wellness trend, blending lifestyle with perceived health benefits. Yet, the country’s food safety culture prioritizes rigorous testing over hype. This approach protects consumers and maintains trust in the food system—a cornerstone of German regulatory philosophy. For businesses, it’s a reminder that innovation must align with compliance.
Germany’s cautious stance also reflects its role within the EU single market. Allowing unauthorized CBD foods could undermine harmonized standards and expose consumers to unverified claims. By enforcing the novel-food regulation, Germany signals its commitment to science-based policy and consumer protection.
The Cost of Compliance
Applying for novel-food authorisation is no small feat. Companies must provide detailed data on composition, manufacturing processes, stability, and toxicology. The process can cost hundreds of thousands of euros and take several years. For small businesses, this barrier often feels insurmountable, pushing them toward riskier shortcuts. But the long-term payoff—legal certainty and market access across the EU—is worth the investment.
Looking Ahead
Germany’s cannabis liberalisation in 2024 sparked optimism, but it didn’t change the rules for CBD foods. Novel-food authorisation remains the gatekeeper. Until EFSA completes its safety review and the EU grants approvals, those CBD brownies are better left off the shelf. The future may hold opportunities, but for now, patience and paperwork are the only legal recipe.
Industry experts predict that once EFSA finalizes its assessment, the market could explode—legally. Approved CBD foods would open doors for innovation, from functional beverages to fortified snacks. Until then, businesses must navigate a regulatory landscape where compliance is king.
See more on GERMANY
Sources
BVL – FAQ zu Hanf, THC, Cannabidiol (CBD)
https://www.bvl.bund.de/DE/Arbeitsbereiche/01Lebensmittel/04AntragstellerUnternehmen/13FAQ/FAQHanfTHCCBD/FAQCannabidiolnode.html
Ongoing
BMEL – Neuartige Lebensmittel (Novel Food)
https://www.bmleh.de/DE/themen/verbraucherschutz/lebensmittelsicherheit/spezielle-lebensmittel/novel-food.html
Ongoing